Eltacin

Eltacin: a Russian drug for the treatment of heart failure

In the modern world, cardiovascular diseases are one of the leading causes of death. Chronic heart failure (CHF) is one of the most common and severe manifestations of cardiovascular pathology. To effectively treat this condition, medicine is developing various pharmacological drugs. One of them is Eltacin, produced by the Russian pharmaceutical company Biotiki MNPC.

Eltacin belongs to the pharmacological group of antioxidants. These are sublingual tablets containing glycine, L-glutamic acid and L-cystine as active substances. Each 220 mg tablet contains 70 mg of each of these components. Excipients include methocel and magnesium stearate.

Eltacin is used in cases of chronic heart failure of functional classes I-III against the background of standard therapy. It helps improve heart function and reduce symptoms of heart failure. The drug is not recommended in case of hypersensitivity to its components.

Possible side effects from using Eltacin include allergic reactions. Interaction of the drug with other drugs may occur when used together with ACE inhibitors, beta-blockers, diuretics, including aldosterone antagonists, and nitrates.

There is no data on an overdose of Eltacin, and there are also no special instructions for its use. However, before starting to use the drug, it is recommended to consult a doctor and carefully read the instructions for medical use of the drug "Eltacin®". Additional information about the drug can be found in the manufacturer's prospectus.

Eltacin is one of the examples of Russian medical achievements in the field of cardiovascular therapy. The development and production of such drugs help improve the quality of life of patients and reduce mortality from cardiovascular diseases. However, before using any medicine, you must consult a doctor and follow his recommendations.

Literature:

1. Instructions for medical use of the drug "Eltacin®".
2. Prospectus of the manufacturer.